DXCM Dexcom Inc

Price (delayed)

$370.38

Market cap

$35.57B

P/E Ratio

149.35

Dividend/share

N/A

EPS

$2.48

Enterprise value

$36.66B

Sector: Healthcare
Industry: Diagnostics & Research

DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring systems for diabetes management. It operates internationally with headquarters in San Diego, California. Dexcom was founded in ...

Highlights

The company's equity has surged by 96% YoY and by 11% QoQ
DXCM's gross profit is up by 41% year-on-year and by 9% since the previous quarter
The quick ratio has declined by 16% since the previous quarter but it has grown by 14% year-on-year
The debt has soared by 61% YoY

Key stats

What are the main financial stats of DXCM
Market
Shares outstanding
96.03M
Market cap
$35.57B
Enterprise value
$36.66B
Valuations
Price to earnings (P/E)
149.35
Price to book (P/B)
23.65
Price to sales (P/S)
19.49
EV/EBIT
116.97
EV/EBITDA
97.91
EV/Sales
20.14
Earnings
Revenue
$1.82B
EBIT
$313.4M
EBITDA
$374.4M
Free cash flow
$264.4M
Per share
EPS
$2.48
Free cash flow per share
$2.76
Book value per share
$15.66
Revenue per share
$19
TBVPS
$39.81
Balance sheet
Total assets
$3.83B
Total liabilities
$2.33B
Debt
$1.76B
Equity
$1.5B
Working capital
$2.73B
Liquidity
Debt to equity
1.18
Current ratio
6.39
Quick ratio
5.87
Net debt/EBITDA
2.91
Margins
EBITDA margin
20.6%
Gross margin
65.4%
Net margin
12.7%
Operating margin
16.3%
Efficiency
Return on assets
7.6%
Return on equity
19.8%
Return on invested capital
8.9%
Return on capital employed
9.4%
Return on sales
17.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

DXCM stock price

How has the Dexcom stock price performed over time
Intraday
0.78%
1 week
4.57%
1 month
4.56%
1 year
57.25%
YTD
0.18%
QTD
0.18%

Financial performance

How have Dexcom's revenue and profit performed over time
Revenue
$1.82B
Gross profit
$1.19B
Operating income
$297M
Net income
$231.1M
Gross margin
65.4%
Net margin
12.7%
The net margin has soared by 200% YoY and by 7% from the previous quarter
DXCM's gross profit is up by 41% year-on-year and by 9% since the previous quarter
Dexcom's revenue has increased by 35% YoY and by 6% from the previous quarter
DXCM's operating income is up by 15% since the previous quarter

Growth

What is Dexcom's growth rate over time

Valuation

What is Dexcom stock price valuation
P/E
149.35
P/B
23.65
P/S
19.49
EV/EBIT
116.97
EV/EBITDA
97.91
EV/Sales
20.14
The stock's price to earnings (P/E) is 16% less than its last 4 quarters average of 177.8
The EPS rose by 11% QoQ
The company's equity has surged by 96% YoY and by 11% QoQ
DXCM's P/B is 15% above its 5-year quarterly average of 20.6 but 8% below its last 4 quarters average of 25.8
The stock's price to sales (P/S) is 61% more than its 5-year quarterly average of 12.1 and 7% more than its last 4 quarters average of 18.2
Dexcom's revenue has increased by 35% YoY and by 6% from the previous quarter

Efficiency

How efficient is Dexcom business performance
Dexcom's ROA has soared by 190% YoY but it has decreased by 2.6% from the previous quarter
The ROE has soared by 180% year-on-year but it is down by 4.8% since the previous quarter
The ROS rose by 8% QoQ

Dividends

What is DXCM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DXCM.

Financial health

How did Dexcom financials performed over time
The company's total assets is 64% higher than its total liabilities
The company's total assets has surged by 75% YoY and by 9% QoQ
The total liabilities has surged by 64% year-on-year and by 8% since the previous quarter
The debt is 18% more than the equity
The company's equity has surged by 96% YoY and by 11% QoQ
DXCM's debt to equity is down by 17% YoY and by 9% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.